glp·helper
glphelper.com/mounjaro/california/apple-valley
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® providers &
prescriptions in Apple Valley, CA

Verified Mounjaro providers in Apple Valley, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Mounjaro weight loss →trial-anchored estimate
city providers
24
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
25 of 25 shown

Find a Mounjaro provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /mounjaro/california/{city}
§ 03Getting Mounjaro in Apple Valley
25 providers · Apple Valley, CA

How to get Mounjaro in Apple Valley.

25 GLP-1 prescribers and 6 local resource types are on record for Apple Valley, plus 3 nearby towns in the directory.

Prescribers in Apple Valley
25 prescribers
25 GLP-1 prescribers in Apple Valley, most listed as Family Medicine (10), Internal Medicine (9) and Family Medicine, Sports Medicine (2). Any California-licensed physician, nurse practitioner, or PA can prescribe Mounjaro, over video or in person. The nearest towns on record are San Bernardino (26 providers), Rialto (27 providers) and Fontana (34 providers).
Around the prescription in Apple Valley
6 listed nearby
13 dietitians, 6 gyms, 4 fitness clubs, 3 trainers, 6 physiotherapists and 1 places to move are on record near Apple Valley.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Zepbound is the FDA-approved tirzepatide for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Apple Valley

Apple Valley, California has a population of 75,791 people. The adult obesity rate in Apple Valley is an age-adjusted estimate of 35.1%, 6 percentage points above the California state rate of 29.1%. Diagnosed diabetes reaches 11.5% of adults in Apple Valley. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 26.3% of adults in Apple Valley.

of Apple Valley adults have obesity
35.1%
diagnosed diabetes
11.5%
no regular physical activity
26.3%

Age-adjusted estimates for Apple Valley, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossdo oral GLP-1 pills work
§ 05Support around Mounjaro in Apple Valley
6 dietitians

The prescription is one part. Here is the rest, in Apple Valley.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Apple Valley, CA, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Melanie Ajanwachuku
RD
Registered dietitian · Metabolic
16133 Kamana Rd
Call 760-242-8491NPI 1427475219
Aleka Arredondo, RDN
RD
Registered dietitian
14161 Quinnault Rd
Call 760-905-8263NPI 1740045152
Natalie Black, RD/RDN
RD
Registered dietitian
26600 Cactus Ave Fl 1
Call 951-486-4000NPI 1124612486
Blake Daly, RD
RD
Registered dietitian
19333 Bear Valley Rd Ste 103
Call 714-618-9500NPI 1568148336
Geraldine Dantas, RD
RD
Registered dietitian
16049 Kamana Rd
Call 760-242-8311NPI 1497295877
Aidan Glauz, RDN
RD
Registered dietitian
18300 Us Highway 18
Call 760-242-2311NPI 1598462681

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

In-Shape Fitness
GYM
4.5 on Google · 1424 reviews
14601 Valley Center Dr
Website
24 Hour Fitness
GYM
4.0 on Google · 608 reviews
18825 Bear Valley Rd
Website
Planet Fitness
GYM
4.5 on Google · 398 reviews
18683 Bear Valley Rd
Website
Legends Barbell
GYM
4.1 on Google · 366 reviews
15321 Palmdale Rd
Website
TG THE GYM
GYM
4.0 on Google · 148 reviews
20240 Outer Hwy 18 N
Website
Anytime Fitness
GYM
4.0 on Google · 98 reviews
13692 Apple Valley Rd
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8 to 2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Mounjaro weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Mounjaro cash price (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Mounjaro providers in California

NPI-verified Mounjaro (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Mounjaro in other states

Find NPI-verified Mounjaro (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Mounjaro in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]